Literature DB >> 12201794

Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.

Xavier Badia1, Fermin Mearin, Agustin Balboa, Eva Baró, Ellen Caldwell, Mercedes Cucala, Manuel Díaz-Rubio, Arturo Fueyo, Julio Ponce, Mentse Roset, Nicholas J Talley.   

Abstract

OBJECTIVES: To evaluate the burden of illness in irritable bowel syndrome (IBS), in terms of resource utilisation (direct and indirect) and health-related quality of life (HR-QOL), in individuals with IBS who meet Rome I and Rome II criteria.
METHODS: A cross-sectional study, carried out by personal interview, on a representative sample (n = 2000) of the Spanish population. Individuals with suspected IBS were identified via a screening question and subsequently given an epidemiological questionnaire to complete. The questionnaire collected information on IBS symptoms, resource utilisation, and HR-QOL [Medical Outcomes Study 36-item Short Form (SF-36)].
RESULTS: Sixty-five individuals met Rome II criteria for IBS, while 146 individuals met exclusively Rome I criteria. Of Rome II individuals, 67.7% had consulted some type of healthcare professional in the previous 12 months, compared with only 41.8% of those individuals meeting exclusively Rome I criteria (p vs 17.1%); 'drug consumption' (70.8 vs 45.2%); and 'reduced performance in main activity' (60 vs 27.4%). Compared with the general population, the study sample reported significantly worse HR-QOL scores in four dimensions of the SF-36 ('bodily pain', 'vitality', 'social functioning' and 'role-emotional'. Additionally, individuals meeting Rome II criteria reported worse HR-QOL scores than those individuals meeting exclusively Rome I criteria, especially in the 'bodily pain' and 'general health' dimensions.
CONCLUSIONS: The burden of illness in IBS is important and correlated to the diagnostic criteria employed. Individuals who met Rome II criteria reported a higher level of resource utilisation and worse HR-QOL than individuals meeting exclusively Rome I criteria.

Entities:  

Mesh:

Year:  2002        PMID: 12201794     DOI: 10.2165/00019053-200220110-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

1.  [Population reference values of the Spanish version of the Health Questionnaire SF-36].

Authors:  J Alonso; E Regidor; G Barrio; L Prieto; C Rodríguez; L de la Fuente
Journal:  Med Clin (Barc)       Date:  1998-10-10       Impact factor: 1.725

2.  Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters.

Authors:  K W Heaton; L J O'Donnell; F E Braddon; R A Mountford; A O Hughes; P J Cripps
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

3.  [Validity of the King's Health questionnaire in the assessment of quality of life of patients with urinary incontinence. The King's Group].

Authors:  X Badia Llach; D Castro Díaz; J Conejero Sugrañes
Journal:  Med Clin (Barc)       Date:  2000-05-06       Impact factor: 1.725

4.  Cost-of-illness studies: fact or fiction?

Authors:  D P Rice
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

Review 5.  Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review.

Authors:  F A Luscombe
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

6.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

7.  Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms.

Authors:  B A Hahn; W B Saunders; W C Maier
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

8.  Trends in Medicare payments in the last year of life.

Authors:  J D Lubitz; G F Riley
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

9.  Irritable bowel syndrome in the general population.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1992-01-11

10.  Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. Quality of Life in COPD Study Group.

Authors:  J Alonso; L Prieto; M Ferrer; G Vilagut; J M Broquetas; J Roca; J S Batlle; J M Antó
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

View more
  14 in total

1.  Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool.

Authors:  Michael D Crowell; Sarah B Umar; Brian E Lacy; Michael P Jones; John K DiBaise; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

2.  A cost analysis of functional bowel disorders in Iran.

Authors:  Delnaz Roshandel; Mohammadreza Rezailashkajani; Sepideh Shafaee; Mohammad Reza Zali
Journal:  Int J Colorectal Dis       Date:  2006-10-25       Impact factor: 2.571

3.  Irritable Bowel Syndrome: Pain in Spain.

Authors:  Fermín Mearin
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

Review 4.  Current perspectives on the diagnosis and treatment of functional esophageal disorders.

Authors:  Roy Dekel; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2003-08

5.  How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.

Authors:  Per A Johansson; Per G Farup; Andrea Bracco; Per O Vandvik
Journal:  BMC Gastroenterol       Date:  2010-03-17       Impact factor: 3.067

6.  Constructive thinking, rational intelligence and irritable bowel syndrome.

Authors:  Enrique Rey; Marta Moreno Ortega; Monica-Olga Garcia Alonso; Manuel Diaz-Rubio
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

Review 7.  Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Authors:  Antona J Wagstaff; James E Frampton; Katherine F Croom
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study.

Authors:  Graeme D Smith; Douglas T Steinke; Moira Kinnear; Kay I Penny; Nim Pathmanathan; Ian D Penman
Journal:  Br J Gen Pract       Date:  2004-07       Impact factor: 5.386

9.  Further validation of the IBS-QOL: female Mexican IBS patients have poorer quality of life than females from North Carolina.

Authors:  Max Schmulson; Orianna Ortiz; Juan Manuel Mejia-Arangure; Yuming B Hu; Carolyn Morris; Denise Arcila; Gabriela Gutierrez-Reyes; Shrikant Bangdiwala; Douglas A Drossman
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.